|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
PT765313E
(pt)
|
1994-06-17 |
2003-11-28 |
Hoffmann La Roche |
Derivados de n,n'-bis(quinolin-4-il)-diamina a sua preparacao e a sua utilizacao como agentes anti-malaria
|
|
WO1996018616A1
(en)
|
1994-12-12 |
1996-06-20 |
Merck & Co., Inc. |
Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
|
|
NZ325248A
(en)
|
1995-12-23 |
1999-09-29 |
Pfizer Res & Dev |
Quinoline and quinazoline compounds useful in therapy
|
|
SE9603285D0
(sv)
|
1996-09-10 |
1996-09-10 |
Astra Ab |
New compounds
|
|
US5874438A
(en)
|
1996-10-11 |
1999-02-23 |
Bayer Aktiengesellschaft |
2,2'-bridged bis-2,4-diaminoquinazolines
|
|
DE69839355T2
(de)
|
1997-07-29 |
2009-06-04 |
Alcon Laboratories, Inc., Fort Worth |
Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
|
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
US20040138284A1
(en)
|
2000-02-11 |
2004-07-15 |
Matthias Wiesner |
Indol-3-yl derivatives
|
|
GB0014022D0
(en)
|
2000-06-08 |
2000-08-02 |
Novartis Ag |
Organic compounds
|
|
WO2002020500A2
(en)
|
2000-09-01 |
2002-03-14 |
Icos Corporation |
Materials and methods to potentiate cancer treatment
|
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
|
CN104744461A
(zh)
|
2001-09-21 |
2015-07-01 |
百时美施贵宝公司 |
含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
|
|
AU2003209321A1
(en)
|
2002-01-18 |
2003-07-30 |
Pharmacia Corporation |
Substituted pyridazinones as inhibitors of p38
|
|
EP1505966A4
(en)
|
2002-05-10 |
2006-08-30 |
Bristol Myers Squibb Co |
1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER
|
|
EP1542948A4
(en)
|
2002-08-23 |
2008-12-17 |
Univ Connecticut |
NEW BIPHENYL AND BIPHENYLENE CANNABINOIDS
|
|
AU2003286711A1
(en)
|
2002-10-25 |
2004-05-13 |
Vertex Pharmaceuticals Incorporated |
Indazolinone compositions useful as kinase inhibitors
|
|
EP1578715B1
(en)
|
2002-12-20 |
2011-03-02 |
Bayer Pharmaceuticals Corporation |
Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
|
|
US20050197350A1
(en)
|
2003-03-31 |
2005-09-08 |
Taisho Pharmaceutical Co., Ltd. |
Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
|
|
TW200503747A
(en)
|
2003-04-22 |
2005-02-01 |
Avanir Pharmaceuticals |
Peptide mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
EP1654002B2
(en)
|
2003-08-07 |
2014-01-29 |
Allergan, Inc. |
Compositions for delivery of therapeutics into the eyes
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
US20060009487A1
(en)
*
|
2004-06-09 |
2006-01-12 |
Sircar Jagadish C |
Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
|
|
BRPI0515500A
(pt)
|
2004-09-20 |
2008-07-29 |
Xenon Pharmaceuticals Inc |
derivados piridazina para inibição de estearoil-coa-desaturase
|
|
WO2006035967A1
(en)
|
2004-09-30 |
2006-04-06 |
Taisho Pharmaceutical Co., Ltd. |
Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
|
|
US7381732B2
(en)
|
2004-10-26 |
2008-06-03 |
Bristol-Myers Squibb Company |
Pyrazolobenzamides and derivatives as factor Xa inhibitors
|
|
WO2006051311A1
(en)
|
2004-11-12 |
2006-05-18 |
Galapagos Nv |
Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
|
|
GB0428082D0
(en)
|
2004-12-22 |
2005-01-26 |
Welcome Trust The Ltd |
Therapeutic compounds
|
|
EP1853573A1
(en)
|
2005-02-25 |
2007-11-14 |
Rigel Pharmaceuticals, Inc. |
Benzisothiazoles useful for treating or preventing hcv infection
|
|
WO2006126081A2
(en)
*
|
2005-05-24 |
2006-11-30 |
Pharmacia & Upjohn Company Llc |
Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
|
|
NZ564222A
(en)
|
2005-06-14 |
2011-10-28 |
Taigen Biotechnology Co Ltd |
Pyrimidine compounds
|
|
US20070203236A1
(en)
|
2006-01-11 |
2007-08-30 |
Smith Jeffrey W |
Novel antagonists of the human fatty acid synthase thioesterase
|
|
JP2007291087A
(ja)
|
2006-03-29 |
2007-11-08 |
Taisho Pharmaceut Co Ltd |
ピリジン誘導体及びその使用に関連する治療法
|
|
HRP20130044T1
(hr)
|
2006-07-25 |
2013-02-28 |
Cephalon, Inc. |
Derivati piridizinona
|
|
WO2008046216A1
(en)
|
2006-10-18 |
2008-04-24 |
Methylgene, Inc. |
Kinase inhibitors and uses thereof
|
|
EP2121619A2
(en)
|
2006-11-24 |
2009-11-25 |
AC Immune S.A. |
Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
|
|
KR101442288B1
(ko)
|
2006-12-13 |
2014-09-19 |
지보당 네덜란드 서비시즈 비.브이. |
카복실산과 퓨린, 피리미딘, 뉴클레오사이드 또는 뉴클레오타이드의 향미 조절 유도체
|
|
NZ584902A
(en)
*
|
2007-10-26 |
2012-03-30 |
Schering Corp |
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
|
|
US7803809B2
(en)
|
2008-11-12 |
2010-09-28 |
Amgen Inc. |
Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
|
|
CN102099036B
(zh)
|
2008-06-03 |
2015-05-27 |
英特芒尼公司 |
用于治疗炎性疾患和纤维化疾患的化合物和方法
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
SG175390A1
(en)
|
2009-04-29 |
2011-12-29 |
Amarin Corp Plc |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
WO2011008931A2
(en)
|
2009-07-15 |
2011-01-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
|
|
SG178106A1
(en)
|
2009-08-05 |
2012-03-29 |
Versitech Ltd |
Antiviral compounds and methods of making and using thereof
|
|
AU2011253058A1
(en)
|
2010-05-13 |
2012-12-06 |
Amgen Inc. |
Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
|
|
WO2011147199A1
(en)
|
2010-05-28 |
2011-12-01 |
Versitech Limited |
Compounds and methods for treating viral infections
|
|
KR20130111512A
(ko)
|
2010-06-04 |
2013-10-10 |
코와 가부시키가이샤 |
광학 활성 디벤질아민 유도체 및 그의 제조 방법
|
|
WO2011163612A1
(en)
|
2010-06-24 |
2011-12-29 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
|
US8450316B2
(en)
|
2010-06-24 |
2013-05-28 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
|
US9050334B2
(en)
|
2010-07-16 |
2015-06-09 |
Innov88 Llc |
MIF inhibitors and their uses
|
|
WO2012016133A2
(en)
|
2010-07-29 |
2012-02-02 |
President And Fellows Of Harvard College |
Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
|
|
US8987271B2
(en)
|
2010-12-22 |
2015-03-24 |
Eutropics Pharmaceuticals, Inc. |
2,2′-biphenazine compounds and methods useful for treating disease
|
|
CN103339110A
(zh)
|
2011-01-28 |
2013-10-02 |
诺瓦提斯公司 |
作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
|
|
WO2012142498A2
(en)
|
2011-04-13 |
2012-10-18 |
Innovimmune Biotherapeutics, Inc. |
Mif inhibitors and their uses
|
|
WO2012162635A1
(en)
|
2011-05-26 |
2012-11-29 |
Sunovion Pharmaceuticals Inc. |
Metabotropic glutamate receptors 5 modulators and methods of use thereof
|
|
US8815909B2
(en)
|
2011-07-18 |
2014-08-26 |
Bristol-Myers Squibb Company |
Diaminocyclohexane compounds and uses thereof
|
|
JP5741850B2
(ja)
|
2011-09-13 |
2015-07-01 |
コニカミノルタ株式会社 |
光学フィルム、それを含む偏光板および液晶表示装置
|
|
MX367352B
(es)
|
2012-01-06 |
2019-08-16 |
Gemphire Therapeutics Inc |
Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
|
|
TW201348231A
(zh)
|
2012-02-29 |
2013-12-01 |
Amgen Inc |
雜雙環化合物
|
|
PT2822936T
(pt)
|
2012-03-07 |
2021-12-02 |
Univ Of Delhi |
Derivados da aminoquinolina e suas utilizações
|
|
JPWO2013137371A1
(ja)
|
2012-03-15 |
2015-08-03 |
興和株式会社 |
新規ピリミジン化合物及びそれらを含有する医薬
|
|
EP2844733B1
(en)
|
2012-04-18 |
2020-07-15 |
Hemoshear, LLC |
In vitro model for pathological or physiologic conditions
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
KR20150059638A
(ko)
|
2012-05-25 |
2015-06-01 |
카타베이시스 파마슈티칼즈, 인코포레이티드 |
전구단백질 전환효소 섭틸리신/켁신 9형 저하 방법
|
|
BR112014030284B1
(pt)
|
2012-07-18 |
2021-11-30 |
Sunshine Lake Pharma Co., Ltd |
Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
|
|
AR092924A1
(es)
|
2012-10-09 |
2015-05-06 |
Sanofi Sa |
Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
AU2013366692B2
(en)
|
2012-12-21 |
2017-11-23 |
Sanofi |
Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
|
|
EP2951157A1
(en)
|
2013-02-04 |
2015-12-09 |
Merck Patent GmbH |
Positive allosteric modulators of mglur3
|
|
TWI644899B
(zh)
|
2013-02-04 |
2018-12-21 |
健生藥品公司 |
Ｆｌａｐ調節劑
|
|
ME03336B
(me)
|
2013-03-12 |
2019-10-20 |
Vertex Pharma |
Inhibitori dnk-pk
|
|
EP2986599A1
(en)
|
2013-04-17 |
2016-02-24 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
US10494442B2
(en)
|
2013-06-07 |
2019-12-03 |
Sanofi Biotechnology |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
US9776995B2
(en)
|
2013-06-12 |
2017-10-03 |
Amgen Inc. |
Bicyclic sulfonamide compounds as sodium channel inhibitors
|
|
AR092240A1
(es)
|
2013-08-26 |
2015-04-08 |
Sunshine Lake Pharma Co Ltd |
Derivados heterociclicos nitrogenados y su aplicacion en farmacos
|
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
|
ES2914978T3
(es)
|
2013-10-11 |
2022-06-20 |
Sanofi Biotechnology |
Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
|
|
CN104558685B
(zh)
|
2013-10-24 |
2017-09-29 |
中国石油化工股份有限公司 |
一种磷氮膨胀型阻燃剂及其合成方法
|
|
JP2017019724A
(ja)
|
2013-10-25 |
2017-01-26 |
第一三共株式会社 |
置換ピリジン化合物および他の医薬の組み合わせ
|
|
EP3080148A2
(en)
|
2013-12-11 |
2016-10-19 |
Glycotope GmbH |
Glycosylated glycophorin peptides
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
TW201609800A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
TW201609798A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
Ｅｘｅｎｄｉｎ－４胜肽類似物
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
LT3119757T
(lt)
|
2014-03-17 |
2018-07-10 |
Pfizer Inc. |
Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme
|
|
AR099937A1
(es)
|
2014-04-04 |
2016-08-31 |
Sanofi Sa |
Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
|
|
JP2017515797A
(ja)
|
2014-04-04 |
2017-06-15 |
サノフイ |
糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての置換インダノン化合物
|
|
TW201625605A
(zh)
|
2014-04-04 |
2016-07-16 |
賽諾菲公司 |
用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
US20170183306A1
(en)
|
2014-05-30 |
2017-06-29 |
Universite Paris Decartes |
Cyclic compounds having a 1,3 diamino-functionality for use in the treatment of hiv infection
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
TWI677489B
(zh)
|
2014-06-20 |
2019-11-21 |
美商基利科學股份有限公司 |
多環型胺甲醯基吡啶酮化合物之合成
|
|
CA2955304C
(en)
|
2014-07-16 |
2023-12-12 |
Sanofi Biotechnology |
Methods for treating high cardiovascular risk patients with hypercholesterolemia
|
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
|
|
WO2016054388A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Glutaminase inhibitors
|
|
NZ734082A
(en)
|
2015-01-20 |
2019-01-25 |
Boehringer Ingelheim Animal Health Usa Inc |
Anthelmintic compounds, compositions and method of using thereof
|
|
WO2016127102A2
(en)
|
2015-02-06 |
2016-08-11 |
Ernesto Abel-Santos |
Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
|
|
BR112017019378A2
(pt)
|
2015-03-18 |
2019-02-19 |
Zealand Pharma A/S |
análogos de amilina
|
|
EP3271405A1
(en)
|
2015-03-20 |
2018-01-24 |
Aarhus Universitet |
Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
|
|
DK3283507T3
(da)
|
2015-04-16 |
2020-01-02 |
Zealand Pharma As |
Acyleret glucagonanalog
|
|
HK1257929A1
(zh)
|
2015-11-06 |
2019-11-01 |
Gemphire Therapeutics Inc. |
治疗混合性血脂异常
|
|
TW201731867A
(zh)
|
2015-12-02 |
2017-09-16 |
賽諾菲公司 |
Ｆｇｆ２１變異體
|
|
AU2016366560A1
(en)
|
2015-12-11 |
2018-06-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
MX381314B
(es)
|
2016-01-20 |
2025-03-12 |
Janssen Sciences Ireland Uc |
Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza
|
|
HK1257556A1
(zh)
|
2016-02-26 |
2019-10-25 |
耀石治疗公司 |
对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗
|
|
PL3429591T3
(pl)
|
2016-03-16 |
2023-07-17 |
Kura Oncology, Inc. |
Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
|
|
JP2019513802A
(ja)
|
2016-04-14 |
2019-05-30 |
ルシー マイケル |
組み合わせ組成物およびその使用方法
|
|
TW201808888A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
WO2018007999A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
US10960020B2
(en)
|
2016-09-15 |
2021-03-30 |
The Brigham And Women's Hospital, Inc. |
Modulation of PCSK9 and LDLR through DRP1 inhibition
|
|
EP4397311A3
(en)
|
2016-10-18 |
2024-10-16 |
Novartis AG |
Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
|
|
US20200038481A1
(en)
|
2016-11-10 |
2020-02-06 |
Csl Limited |
Reconstituted high density lipoprotein treatment of myocardial infarction
|
|
JOP20190112A1
(ar)
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
WO2018106820A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
WO2018106818A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
AR110351A1
(es)
|
2016-12-13 |
2019-03-20 |
Bristol Myers Squibb Co |
COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa
|
|
CA3072274C
(en)
|
2017-02-08 |
2024-01-02 |
Brooke Schumm |
Intra-operative radiation therapy capsule with cylindrical shell radiation containment shutter system
|
|
PE20191716A1
(es)
|
2017-02-08 |
2019-12-05 |
Bristol Myers Squibb Co |
Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
|
|
AR110988A1
(es)
|
2017-02-21 |
2019-05-22 |
Sanofi Sa |
Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
|
|
WO2018165718A1
(en)
|
2017-03-17 |
2018-09-20 |
Cardio Therapeutics Pty Ltd |
Heterocyclic inhibitors of pcsk9
|
|
WO2018175746A1
(en)
|
2017-03-24 |
2018-09-27 |
Kura Oncology, Inc. |
Methods for treating hematological malignancies and ewing's sarcoma
|
|
CN110506056A
(zh)
|
2017-04-21 |
2019-11-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体和其使用方法
|
|
JP7252908B2
(ja)
|
2017-06-14 |
2023-04-05 |
トレベナ・インコーポレイテッド |
Ｓ１ｐ１活性を調節するための化合物およびその使用法
|
|
JP6928986B2
(ja)
|
2017-06-26 |
2021-09-01 |
深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． |
キナーゼ活性を阻害するためのインダゾール系化合物、その組成物および使用
|
|
CN109384712B
(zh)
|
2017-08-14 |
2021-05-07 |
北京宽厚医药科技有限公司 |
靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
|
|
WO2019079701A1
(en)
|
2017-10-20 |
2019-04-25 |
Dana-Farber Cancer Institute, Inc. |
HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
|
|
JP2021501210A
(ja)
|
2017-10-30 |
2021-01-14 |
モントリオール ハート インスティテュート |
血漿コレステロールの上昇を処置する方法
|
|
PE20210119A1
(es)
|
2017-10-31 |
2021-01-19 |
Staten Biotechnology B V |
Anticuerpos anti-apoc3 y metodos de uso de estos
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
EA202091269A1
(ru)
|
2017-11-21 |
2020-08-07 |
Бристол-Маерс Сквибб Компани |
Сульфон-, пиридин-, алкил-, амид-замещенные гетероарильные соединения
|
|
WO2019111225A1
(en)
|
2017-12-08 |
2019-06-13 |
Avaliv Therapeutics |
Compounds and methods for the treatment of non‑alcoholic steatohepatitis
|
|
SG11202005146VA
(en)
|
2017-12-18 |
2020-06-29 |
Regeneron Pharma |
Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
|
|
JP7466448B2
(ja)
|
2018-01-17 |
2024-04-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ｄｎａ－ｐｋ阻害剤
|
|
US11513131B2
(en)
|
2018-01-22 |
2022-11-29 |
Global Genomics Group, LLC |
Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof
|
|
WO2019147650A1
(en)
|
2018-01-23 |
2019-08-01 |
Gila Therapeutics, Inc. |
Peptide yy pharmaceutical formulations, compositions, and methods
|
|
CA3093469A1
(en)
|
2018-03-09 |
2019-09-12 |
The Brigham And Women's Hospital, Inc. |
Combination therapy for cardiovascular diseases
|
|
CN111936486B
(zh)
|
2018-03-22 |
2023-09-22 |
百时美施贵宝公司 |
用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
|
|
CN110384801B
(zh)
|
2018-04-20 |
2021-09-14 |
中国科学院上海药物研究所 |
miRNA552簇的微小RNA在治疗LDLC相关代谢性疾病中的应用
|
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
US20190374526A1
(en)
|
2018-06-06 |
2019-12-12 |
Merck Sharp & Dohme Corp. |
Substituted Heterocyclic Compounds as Inhibitors of PRDM9
|
|
US11442072B2
(en)
|
2018-07-10 |
2022-09-13 |
Jenny and Antti Wihuri Foundation |
Method for measuring LDL aggregation
|
|
US11254660B2
(en)
|
2018-08-31 |
2022-02-22 |
Pfizer Inc. |
Combinations for treatment of NASH/NAFLD and related diseases
|
|
KR20210070300A
(ko)
|
2018-10-03 |
2021-06-14 |
스태튼 바이오테크놀로지 비.브이. |
사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법
|
|
JP7631193B2
(ja)
|
2018-10-22 |
2025-02-18 |
アルミス インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
KR20260037169A
(ko)
|
2018-11-09 |
2026-03-17 |
노파르티스 아게 |
apo(a)를 표적화하는 콘쥬게이션된 안티센스 화합물로 심혈관 사건의 위험을 감소시키는 방법
|
|
US12399188B2
(en)
|
2018-12-06 |
2025-08-26 |
Zora Biosciences Oy |
Biomarkers for cardiovascular events
|
|
BR112021013807A2
(pt)
*
|
2019-01-18 |
2021-11-30 |
Astrazeneca Ab |
Inibidores de pcsk9 e seus métodos de uso
|
|
MX2021008661A
(es)
*
|
2019-01-18 |
2021-08-19 |
Astrazeneca Ab |
Inhibidores de la pcsk9 y metodos de uso de los mismos.
|
|
CN111484480B
(zh)
|
2019-01-29 |
2023-08-11 |
上海翰森生物医药科技有限公司 |
一种多环类衍生物抑制剂、其制备方法和应用
|
|
CA3128368A1
(en)
|
2019-02-01 |
2020-08-06 |
Memorial Sloan Kettering Cancer Center |
Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
|
|
US20200390858A1
(en)
|
2019-04-17 |
2020-12-17 |
Ngm Biopharmaceuticals, Inc. |
Combination Therapy for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases
|
|
WO2020234726A1
(en)
|
2019-05-20 |
2020-11-26 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
WO2021119321A1
(en)
|
2019-12-10 |
2021-06-17 |
Regeneron Pharmaceuticals, Inc. |
Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
|
|
WO2021209808A1
(en)
|
2020-04-16 |
2021-10-21 |
Abionyx Pharma Sa |
Cer-001 therapy for treating kidney disease
|
|
CN113713107B
(zh)
|
2020-05-26 |
2022-09-23 |
中国科学院上海药物研究所 |
miRNA552簇的微小RNA在治疗糖脂代谢病中的应用
|
|
CA3179316A1
(en)
|
2020-05-29 |
2021-12-02 |
Andrew W. HAMER |
Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
|
|
WO2021250069A1
(en)
|
2020-06-10 |
2021-12-16 |
Christian-Albrechts-Universität Zu Kiel |
Pharmaceutical compound for the treatment of atherosclerotic cardiovascular disease
|
|
US20240002354A1
(en)
|
2020-08-05 |
2024-01-04 |
Rezubio Pharmaceuticals Co., Ltd |
Antidiabetic compounds and compositions
|
|
EP4243805A1
(en)
|
2020-08-07 |
2023-09-20 |
Gbiotech S.À.R.L. |
Combination therapies for treating coronavirus infection
|
|
US12472171B2
(en)
|
2020-08-19 |
2025-11-18 |
Biogen Ma Inc. |
Methods for treating hypercholesterolemia
|
|
KR20230069969A
(ko)
|
2020-09-15 |
2023-05-19 |
리제너론 파마슈티칼스 인코포레이티드 |
통증에 대한 lepr 아고니스트의 사용
|
|
AU2020472970A1
(en)
|
2020-10-20 |
2023-06-22 |
Halo Therapeutics Ltd |
Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor
|
|
AU2021373780A1
(en)
|
2020-11-05 |
2023-06-08 |
Amgen Inc. |
METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
|
|
EP4011877A3
(en)
|
2020-12-11 |
2023-01-11 |
Institut de Cardiologie de Montréal |
Method of treating elevated plasma cholesterol
|
|
US20240044924A1
(en)
|
2020-12-11 |
2024-02-08 |
Helsingin Yliopisto |
Method for determining a likelihood of a subject to respond to lipid lowering therapy
|
|
EP4294257B1
(en)
|
2021-02-22 |
2025-11-05 |
Regeneron Pharmaceuticals, Inc. |
Method for diagnosing and treating partial lipodystrophy
|
|
US20250281495A1
(en)
|
2021-02-25 |
2025-09-11 |
Icahn School Of Medicine At Mount Sinai |
Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease
|
|
CA3212583A1
(en)
|
2021-03-27 |
2022-10-06 |
Daniel Gooding |
Compositions having improved bioavailability of therapeutics
|
|
AU2022299514A1
(en)
|
2021-06-24 |
2024-01-18 |
Sirnaomics, Inc. |
Products and compositions
|
|
AU2022297535A1
(en)
|
2021-06-25 |
2024-01-04 |
Amgen Inc. |
Treatment of cardiovascular disease with trem-1 antigen binding proteins
|
|
EP4370519A1
(en)
|
2021-07-14 |
2024-05-22 |
Eternygen UK Ltd. |
5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives for use in the treatment of diseases responsive to citrate transporter modulation
|
|
WO2023052783A1
(en)
|
2021-09-30 |
2023-04-06 |
Sitryx Therapeutics Limited |
Novel compounds
|
|
WO2023079294A1
(en)
|
2021-11-05 |
2023-05-11 |
Sitryx Therapeutics Limited |
Phthalazine derivatives as pyruvate kinase modulators
|
|
JP2024546039A
(ja)
|
2021-11-12 |
2024-12-17 |
シェンチェン ジンタイ テクノロジー カンパニー リミテッド |
アスパラギン酸誘導体並びに肝線維症及び非アルコール性肝炎などの代謝性疾患の治療におけるその使用
|
|
CN114277032A
(zh)
|
2021-12-31 |
2022-04-05 |
华中科技大学同济医学院附属协和医院 |
一种低密度脂蛋白受体基因突变体及其应用
|
|
US20250223281A1
(en)
|
2022-01-14 |
2025-07-10 |
Rezubio Pharmaceuticals Co., Ltd |
Antidiabetic compounds and compositions
|
|
TW202345865A
(zh)
|
2022-01-24 |
2023-12-01 |
大陸商上海舶望製藥有限公司 |
抑制LPA(Apo(a))蛋白表達的組合物和方法
|
|
CN116617390A
(zh)
|
2022-02-11 |
2023-08-22 |
武汉大学 |
Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用
|
|
US20250177377A1
(en)
|
2022-03-11 |
2025-06-05 |
University Of Florida Research Foundation, Incorporated |
Targeting ptchd1 and neuronal cholesterol to enhance safety of opioid analgesics
|
|
US20230338419A1
(en)
|
2022-03-21 |
2023-10-26 |
The Trustees Of The University Of Pennsylvania |
Methods and apparatus for diagnosis and detection of cardiac allograft vasculopathy
|
|
CN116948030B
(zh)
|
2022-04-25 |
2024-11-19 |
武汉大学 |
抗asgr1单克隆抗体及其应用
|
|
CN117045715B
(zh)
|
2022-05-13 |
2025-06-06 |
浙江养生堂天然药物研究所有限公司 |
红肉苹果和樱桃李组合物及其在抗动脉粥样硬化方面的应用
|
|
CN115581694A
(zh)
|
2022-11-10 |
2023-01-10 |
正大青春宝药业有限公司 |
洋川芎内脂i在制备治疗高血脂症药物中的应用
|
|
CN117180404A
(zh)
|
2023-10-24 |
2023-12-08 |
清华大学 |
Cholesin在调节胆固醇稳态中的用途
|
|
CN117482076A
(zh)
|
2023-11-24 |
2024-02-02 |
中国人民解放军陆军军医大学第二附属医院 |
甲硫氨酸类化合物在制备pcsk9抑制剂中的应用
|